Teva Should Face Key Copaxone Antitrust Claims, Court Told
By Bryan Koenig · March 3, 2025, 8:53 PM EST
Mylan and pharmaceutical wholesalers should be allowed to proceed with some, but not all, parallel claims accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic...
To view the full article, register now.